Video

Abzena Capacity Update October 2025: Large Molecule

Source: Abzena
  • AbZelectPRO™, AbZelectPRO™-KO, and AbZelectPRO™ -KO+ - mammalian CLD platforms enable the rapid progression from DNA to RCB in 10 weeks for therapeutic antibodies & difficult-to-express protein
  • Robust CHO-K1 & GS Knockout expression systems are combined with de-risked CLD workflows and next-gen 2G UNic® vector technology to offer enhanced productivity and high-quality titers up to 10g/L
  • Backed by an extensive in-house analytical portfolio, which ensures an efficient, stable, & scalable production - simplifying the IND application process and delivering customers’ complex biologics successfully to the clinic

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Abzena